Home » News » Nephrology » Cardiovascular Disease (CVD)
Cardiovascular Disease (CVD)
CARDIOVASCULAR DISEASE (CVD)
Model predicts overall and heart failure hospitalization-free survival and treatment benefit in HFrEF
Findings seen for people with or without type 2 diabetes, but similar trend not seen for those with type 1 diabetes
Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.
An investigation explored associations between rapid kidney function decline and increased heart failure risk in individuals with type 2 diabetes.
Long-term health-related quality of life consistently high up to 20 years after the event
Elevated serum uric acid levels showed significant relationships with all-cause and cardiovascular death, but not cancer death.
Empagliflozin is a sodium-glucose co-transporter 2 inhibitor.
Predicted probability of success of future larger trial was 25% and 14% for <140 and <160 mm Hg, respectively
Investigators found a “dose-response” relationship between the level of residual kidney function and survival benefits.
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban
Load More
Open
Next post in Cardiovascular Disease (CVD)
Close
Close more info about Novel Model Aids Prediction of Survival in Heart Failure With Reduced Ejection Fraction
Loading...
Close more info about Novel Model Aids Prediction of Survival in Heart Failure With Reduced Ejection Fraction
Loading...